Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: Preliminary results

Journal of Clinical Oncology

Volumn 23, Issue 33, 2005, Pages 8461-8468

  Zhang, Li ^a   Zhao, Chong ^a   Peng, Pei Jian ^a   Lu, Li Xia ^a   Huang, Pei Yu ^a   Han, Fei ^a   Wu, Shao Xiong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; ARTICLE; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSESTHESIA; DYSPHAGIA; FEMALE; HUMAN; HYPESTHESIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CARCINOMA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; XEROSTOMIA; CHINA; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; NASOPHARYNX TUMOR; NONPARAMETRIC TEST; PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC AGENTS; CHINA; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 33644668130     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.00.3863     Document Type: Article

References (46)

1. Fandi A, Altun M, Azli N, et al: Nasopharyngeal cancer, epidemiology, staging and treatment. Semin Oncol 21:382-397, 1994
2. Ho JHC: An epidemiological and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 4:183-197, 1978
3. Zhang EP, Liang PG, Cai KL, et al: Radiation therapy of nasopharyngeal carcinoma: Prognostic factors based on a 10-year follow-up of 1302 patients. Int J Radiat Oncol Biol Phys 16:301-305, 1989
4. Lee AWM, Poon YF, Foo W, et al: Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: Overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 23:261-270, 1992
5. Choo R, Tannock I: Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx: A review of the Princess Margaret Hospital experience. Cancer 68:2120-2124, 1991
6. Chan A, Teo P, Leung T, et al: The role of chemotherapy in the management of nasopharyngeal carcinoma. Cancer 82:1003-1012, 1998
7. Al-Kourainy K, Crissman J, Ensley J, et al: Excellent response to cisplatin based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma. Am J Clin Oncol 11:427-430, 1988
8. Siu LL, Czaykowski PM, Tannock I: Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. J Clin Oncol 16:2514-2521, 1998
9. Su WC, Chen TY, Kao RH, et al: Chemotherapy with cisplatin and continuous infusion of 5-fluorouracil and bleomycin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan. Oncology (Basel) 50:205-208, 1993
10. Boussen H, Cvitrovic E, Wendling JL: Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin and fluorouracil. J Clin Oncol 9:1675-1681, 1991
11. Bachouchi M, Cvitkovic E, Azli N, et al: High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy. J Natl Cancer Inst 82:616-620, 1990
12. Tan EH, Khoo KS, Wee J, et al: Phase II trial of paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 10:235-237, 1999
13. Caponigro F, Massa E, Manzione L, et al: Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: A phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 12:199-202, 2001
14. Mathe G, Kidani Y, Segiguchi M, et al: Oxalato-platinum or L-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 43:237-250, 1989
15. Mathe G, Kidani Y, Noji M, et al: Antitumor activity of L-OHP in mice. Cancer Lett 27:135-143, 1985
16. Extra JM, Espie M, Calvo F, et al: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299-303, 1990
17. Raymond E, Faivre S, Woynarowski JM, et al: Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 25:4-12, 1998 (suppl 5)
18. Raymond E, Chaney A, Taamma A, et al: Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 9:1053-1071, 1998
19. Rixe O, Ortuzar W, Alvarez M, et al: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem Pharmacol 52:1855-1865, 1996
20. De Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
21. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
22. Levi F, Zidani R, Brienza S, et al: A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma: International Organization for Cancer Chronotherapy. Cancer 85:2532-2540, 1999
23. Janinis J, Papakostas P, Samelis G, et al: Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: A Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Ann Oncol 11:163-167, 2000
24. Degardin M, Cappelaere P, Krakowski I, et al: Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol 32B:278-279, 1996
25. Magne N, Fischel JL, Formento P, et al: Oxaliplatin-5-fluorouracil and ionizing radiation: Importance of the sequence and influence of P53 status. Oncology 64:280-287, 2003
26. McMullen KP, Blackstock AW: Chemoradiation with novel agent for rectal cancer. Clin Colorectal Cancer 2:24-30, 2002
27. Al-Sarraf M, LeBlanc M, Giri PGS, et al: Chemoradiotherapy vs radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup Study 0099. J Clin Oncol 16:1310-1317, 1998
28. Fleming ID, Cooper JS, Henson DE: AJCC Cancer Staging Manual. Philadelphia, PA, Lippincott-Raven, 1997
29. Ma J, Mai HQ, Hong MH, et al: Result of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 19:1350-1357, 2001
30. Zhang EP, Luo W, Qian JY, et al: A study on improving the treatment technique of the radiotherapy in nasopharyngeal carcinoma: Part I. The dose distribution of target volume. Chinese J Cancer 14:126-129, 1996
31. Chao Y, Yeh KH, Chang CJ, et al: Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 91:453-458, 2004
32. Zhang L, Peng PJ, Zhao C: Randomized phase II clinical study comparing standard RT with or without weekly oxaliplatin in treatment of locally advanced NPC: Preliminary result. Proc Am Soc Clin Oncol 22:498, 2003 (abstr 2003)
33. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
34. Caussanel JP, Levi F, Brienza S, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J Natl Cancer Inst 82:1046-1050, 1990
35. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
36. Mantel N: Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
37. Breslow NE: A generalized Kruskal and Wallis test for comparing k samples subject to unequal patterns of censorship. Biometrika 57:579-594, 1970
38. International Nasopharyngeal Cancer Study Group: Preliminary results of the randomized trial comparing neoadjuvant chemotherapy (cisplatinum, epirubicin, bleomycin) plus radiotherapy vs radiotherapy alone in stage IV (≥ N2, M0) undifferentiated nasopharyngeal cancer. Int J Radiat Oncol Biol Phys 35:463-469, 1996
39. Rossi A, Molinari R, Boracchi P, et al: Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: Results of a 4-year multicenter randomized study. J Ciin Oncol 6:1401-1410, 1988
40. Fu KK: Combined-modality therapy for head and neck cancer. Oncology 11:1781-1790, 1796, 1997
41. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data-MACH-NC Collaborative Group: Meta-analysis of chemotherapy on head and neck cancer. Lancet 355:949-955, 2000
42. Lin J-C, Jan J-S, Hsu C-Y, et al: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival. J Clin Oncol 21:631-637, 2003
43. Chan ATC, Teo PML, Ngan RK, et al: Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20:2038-2044, 2002
44. Cooper JS: Concurrent chemotherapy and radiation therapy for advanced stage carcinoma of the nasopharynx. Int J Radiat Oncol Biol Phys 48:1277-1279, 2000
45. Tan EH, Chua ET, Wee J, et al: Concurrent chemoradiotherapy followed by adjuvant chemotherapy in Asian patients with nasopharyngeal carcinoma: Toxicities and preliminary results. Int J Radiat Oncol Biol Phys 45:597-601, 1999
46. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004